Prognostic Value of Prothrombin Fragments 1+2 for Pulmonary Embolism Incidence
1 other identifier
observational
N/A
1 country
1
Brief Summary
To determine the possible association of prothrombin fragments 1+2 elevation with incidents of pulmonary embolism in patients with COPD exacerbation.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 1, 2010
CompletedFirst Posted
Study publicly available on registry
March 2, 2010
CompletedMarch 2, 2010
March 1, 2010
March 1, 2010
March 1, 2010
Conditions
Study Arms (1)
COPD exacerbation
Patients admitted to hospital with COPD exacerbation
Interventions
Eligibility Criteria
Patients admitted to hospital due to COPD exacerbation
You may qualify if:
- COPD exacerbation
- Able to give informed consent
- Able to perform spirometry
You may not qualify if:
- Known malignancy
- Known hypercoagulable state
- Receiving anticoagulant treatment
- Pregnancy
- Renal failure
- Allergy to Iodine
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Hillel Yaffe Medical Center
Hadera, 38100, Israel
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER GOV
Study Record Dates
First Submitted
March 1, 2010
First Posted
March 2, 2010
Last Updated
March 2, 2010
Record last verified: 2010-03